|
Each year around 75,000 Americans are diagnosed with atrial fibrillation (AF), 900,000 experience a venous thromboembolism event (VTE), and 800,000 have a stroke. The burden for those who survive is enormous and the cost of care a major expense for individuals and the nation. Stroke alone costs around $73.7 billion annually. Fortunately research advances are offering significant hope. A number of investigative anticoagulants have the potential to reduce strokes in AF patients while also reducing the risk of bleeds; clot-dissolving agents are proving to lessen the effects of strokes; and the same drugs in the pipeline for AF could prevent VTE after major orthopedic surgery.
Advances in thrombosis continue to offer breakthroughs, making it critical that we ensure support and incentives for future research, and that innovation remain the bedrock of good public policy. By bringing this resource to those shaping public health policy, the Alliance for Aging Research aims to enrich the national debate on health care and on chronic diseases of aging.
Browse facts in these categories:
|